| Erik Eyring, CRNA | |
|
2600 Sixth Street Sw, Ohio Hospital Based Physician Corp, Canton, OH 44710 | |
| (330) 363-7462 | |
| (330) 363-7679 |
| Full Name | Erik Eyring |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 19 Years |
| Location | 2600 Sixth Street Sw, Canton, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104880020 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | COA08567NA (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aultman Hospital | Canton, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aultman Deuble Heart And Vascular Hospital, Llc | 1850726126 | 87 |
| Ohio Hospital-based Physicians Corporation | 9133019110 | 65 |
News Archive
The world is grappling with the spread of coronavirus disease (COVID-19), caused by a novel coronavirus called SARS-CoV-2. In most countries across the globe, the virus is spreading rapidly, sparking panic.
Bristol-Myers Squibb Company announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).
The October issue of GIE: Gastrointestinal Endoscopy features several new studies evaluating various treatments for Barrett's esophagus (BE). Two of these studies are highlighted below. BE is a condition in which there are unusual changes to the cells lining the esophagus. It is believed to be most commonly due to inflammation from gastroesophageal reflux disease (GERD).
Only about 54% of medical practitioners surveyed say they have prescribed pre-exposure prophylaxis, or PrEP, to HIV-vulnerable patients, according to a new study by a Vanderbilt University Medical Center investigator.
› Verified 6 days ago
| Entity Name | Ohio Hospital-based Physicians Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891727079 PECOS PAC ID: 9133019110 Enrollment ID: O20040316000515 |
News Archive
The world is grappling with the spread of coronavirus disease (COVID-19), caused by a novel coronavirus called SARS-CoV-2. In most countries across the globe, the virus is spreading rapidly, sparking panic.
Bristol-Myers Squibb Company announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).
The October issue of GIE: Gastrointestinal Endoscopy features several new studies evaluating various treatments for Barrett's esophagus (BE). Two of these studies are highlighted below. BE is a condition in which there are unusual changes to the cells lining the esophagus. It is believed to be most commonly due to inflammation from gastroesophageal reflux disease (GERD).
Only about 54% of medical practitioners surveyed say they have prescribed pre-exposure prophylaxis, or PrEP, to HIV-vulnerable patients, according to a new study by a Vanderbilt University Medical Center investigator.
› Verified 6 days ago
| Entity Name | Aultman Deuble Heart & Vascular Hospital, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306495718 PECOS PAC ID: 1850726126 Enrollment ID: O20200114002347 |
News Archive
The world is grappling with the spread of coronavirus disease (COVID-19), caused by a novel coronavirus called SARS-CoV-2. In most countries across the globe, the virus is spreading rapidly, sparking panic.
Bristol-Myers Squibb Company announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).
The October issue of GIE: Gastrointestinal Endoscopy features several new studies evaluating various treatments for Barrett's esophagus (BE). Two of these studies are highlighted below. BE is a condition in which there are unusual changes to the cells lining the esophagus. It is believed to be most commonly due to inflammation from gastroesophageal reflux disease (GERD).
Only about 54% of medical practitioners surveyed say they have prescribed pre-exposure prophylaxis, or PrEP, to HIV-vulnerable patients, according to a new study by a Vanderbilt University Medical Center investigator.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erik Eyring, CRNA Po Box 80690, Canton, OH 44708-0690 Ph: (330) 363-7444 | Erik Eyring, CRNA 2600 Sixth Street Sw, Ohio Hospital Based Physician Corp, Canton, OH 44710 Ph: (330) 363-7462 |
News Archive
The world is grappling with the spread of coronavirus disease (COVID-19), caused by a novel coronavirus called SARS-CoV-2. In most countries across the globe, the virus is spreading rapidly, sparking panic.
Bristol-Myers Squibb Company announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).
The October issue of GIE: Gastrointestinal Endoscopy features several new studies evaluating various treatments for Barrett's esophagus (BE). Two of these studies are highlighted below. BE is a condition in which there are unusual changes to the cells lining the esophagus. It is believed to be most commonly due to inflammation from gastroesophageal reflux disease (GERD).
Only about 54% of medical practitioners surveyed say they have prescribed pre-exposure prophylaxis, or PrEP, to HIV-vulnerable patients, according to a new study by a Vanderbilt University Medical Center investigator.
› Verified 6 days ago
Sarah Gomez, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4665 Douglas Cir Nw, Canton, OH 44718 Phone: 330-499-5700 | |
Roxie Lee Rush, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2600 Sixth Street Sw, Ohio Hospital Based Physician Corp, Canton, OH 44710 Phone: 330-363-7462 Fax: 330-363-7679 | |
Mr. Kevin White, C.R.N.A. Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2600 Sixth St Sw, Canton, OH 44710 Phone: 330-363-7462 Fax: 330-363-7679 | |
Amanda G Gillis, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4665 Douglas Cir Nw, #100, Canton, OH 44718 Phone: 330-499-5700 Fax: 330-498-4229 | |
Arlene Ann Weeber, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2600 6th St Sw, Ohio Hospital Based Physician Corp, Canton, OH 44710 Phone: 330-363-7462 Fax: 330-363-7679 | |
Sheree Boyle, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2600 Sixth St Sw, Canton, OH 44710 Phone: 330-363-7462 Fax: 330-363-7679 | |
Lois R Milosevic, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1320 Mercy Dr Nw, Canton, OH 44708 Phone: 330-489-1111 |